All In Biotech

NDA 019766 · Organon

Zocor

Simvastatin · Oral · HMG-CoA Reductase Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Aug 9, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Dec 23, 1991

Approved uses

14

Original approval plus efficacy supplements

Registered trials

616

177 Phase 3, 25 recruiting

FAERS reports

250,259

182,048 serious, 22,333 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 28, 2025.

ZOCOR ® is indicated: To reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. ZOCOR is an HMG-CoA reductase inhibitor indicated: ( 1 ) To reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia.

Mechanism: Simvastatin is a prodrug and is hydrolyzed to its active β-hydroxyacid form, simvastatin acid, after administration. Simvastatin acid and its metabolites are inhibitors of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a precursor of cholesterol.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • ZOCOR · SIMVASTATIN 80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • ZOCOR · SIMVASTATIN 20MG · TABLET, ORAL · Prescription · TE AB
  • ZOCOR · SIMVASTATIN 5MG · TABLET, ORAL · Prescription · TE AB
  • ZOCOR · SIMVASTATIN 40MG · TABLET, ORAL · Prescription · TE AB
  • ZOCOR · SIMVASTATIN 10MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Simvastatin" as an intervention, any sponsor and status, largest first.

All 616 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue13,917
  • nausea13,264
  • dyspnoea12,719
  • diarrhoea12,137
  • drug ineffective11,641
  • dizziness11,247
  • fall9,357
  • pain9,317
  • asthenia9,294
  • headache9,088
  • myalgia8,514
  • vomiting8,304

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044,826
20055,604
20065,584
20075,313
20086,331
20098,494
201012,182
201113,612
201214,724
201313,177
201415,320
201518,481
201618,178
201715,969
201818,589
201916,748
202013,124
20219,920
20229,186
20237,747
20246,694
20256,160
20264,290

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zocor (Simvastatin)

2024 spending

$1.6M

Beneficiaries

692

2,681 claims

Per beneficiary

$2,262

$8.10 per unit

View as table
YearSpending
2020$0
2021$603,570
2022$1,850,570
2023$1,786,185
2024$1,565,299

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,155 on PubMed

Sponsor: Organon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.